Authors
Latest:
Dr. Lockhart on Dual-Immunotherapy Strategies in CRCA. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).
Latest:
Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx CancerA. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.
Latest:
Dr. McCollum on the Clinical Utility of Regorafenib in mCRCA. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).
Latest:
Dr. Chien on Tucatinib in HER2+ Breast CancerA. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.
Latest:
Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO TrialA. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.
Latest:
Final Thoughts on Case Study and Treating Multiple MyelomaDr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.
Latest:
Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPCOliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.
Latest:
When Patients Refuse Treatment for Their CancerQuoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.
Latest:
A Day In the Life of a Pediatric OncologistAs a practicing pediatric oncologist at an academic institute, every morning begins with optimism and a quest to win the day.
Latest:
Dr. Katz on Redefining Risk Stratification in Prostate CancerAaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.
Latest:
Navigating Myelofibrosis: Updates for Community Hematologist OncologistsDrs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.
Latest:
Dr. Goodman on the Need for Molecular Subtyping in T-Cell LymphomasAaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.
Latest:
Dr. Logan Discusses Acalabrutinib in CLLAaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.
Latest:
Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in MesotheliomaAaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.
Latest:
Potential Applications of Immune Checkpoint Blockade for MesotheliomaMalignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.
Latest:
Common Adverse Effects of Anti-HER2 Therapies and Practical Management RecommendationsThe benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.
Latest:
Dr. Master on the Mediterranean Diet in Relation to Breast Cancer RiskAashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.
Latest:
Dr. Nabid on a Shorter Duration of ADT in Prostate CancerAbdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.
Latest:
Exploring the Future of MF TreatmentThe panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.
Latest:
Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple MyelomaAbhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.
Latest:
The Role of Radiation in the Management of Brain MetastasesIn this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Latest:
Dr. Caudle on Upcoming Breast Cancer Trial ResultsAbigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.
Latest:
Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung CancerAbraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.
